We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $13 · 4 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Kamada: Undervalued, Yet Execution Risks Keep It A Hold (NASDAQ:KMDA) - Seeking Alpha
Kamada: Undervalued, Yet Execution Risks Keep It A Hold (NASDAQ:KMDA) Seeking Alpha
Kamada (KMDA) Receives FDA Nod for New Fluorescent Focus Inhibition Test - GuruFocus
Kamada (KMDA) Receives FDA Nod for New Fluorescent Focus Inhibition Test GuruFocus
Kamada secures FDA approval for in-house rabies testing lab - grafa.com
Kamada secures FDA approval for in-house rabies testing lab grafa.com
Kamada receives FDA approval for rabies antibody testing lab By Investing.com - Investing.com South Africa
Kamada receives FDA approval for rabies antibody testing lab By Investing.com Investing.com South Africa
Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory - The Manila Times
Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory The Manila Times
Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 12. | After market close (AMC) | $0.11 | — | — | $146.98M | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2025. 12. 09. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 05. 15. | Benchmark | — | Maintain | Buy → Buy | — | Benchmark: Buy |
| 2025. 03. 21. | Benchmark | — | Initiate coverage | — → Buy | — | Benchmark: Buy |
| 2025. 03. 06. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 01. 10. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2024. 11. 15. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
Price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 194,245 | $1.62B | 0.00% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 140,682 | $993.22M | 0.00% | — | New position |